Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT00036114

Collaborator

(none)

Locations

Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.

Condition or Disease	Intervention/Treatment	Phase
Alzheimer Disease	Drug: aripiprazole	Phase 3

Study Design

Study Type:

Interventional

Primary Purpose:

Treatment

Study Start Date :

Mar 1, 2000

Actual Primary Completion Date :

Aug 1, 2003

Actual Study Completion Date :

Aug 1, 2003

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

55 Years to 95 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Institutionalized patients with Alzheimer's

Contacts and Locations

Locations

	Site	City	State	Country
1	Local Institution	Tuscaloosa	Alabama	United States
2	Local Institution	Scottsdale	Arizona	United States
3	Local Institution	Cerritos	California	United States
4	Local Institution	Granada Hills	California	United States
5	Local Institution	Los Angeles	California	United States
6	Local Institution	San Diego	California	United States
7	Local Institution	Torrance	California	United States
8	Local Institution	Denver	Colorado	United States
9	Local Institution	Hamden	Connecticut	United States
10	Local Institution	Miami	Florida	United States
11	Local Institution	North Miami Beach	Florida	United States
12	Local Institution	West Palm Beach	Florida	United States
13	Local Institution	Atlanta	Georgia	United States
14	Local Institution	Augusta	Georgia	United States
15	Local Institution	Macon	Georgia	United States
16	Local Institution	Honolulu	Hawaii	United States
17	Local Institution	North Chicago	Illinois	United States
18	Local Institution	Springfield	Illinois	United States
19	Local Institution	New Orleans	Louisiana	United States
20	Local Institution	Shreveport	Louisiana	United States
21	Local Institution	Baltimore	Maryland	United States
22	Local Institution	Newton Center	Massachusetts	United States
23	Local Institution	Springfield	Massachusetts	United States
24	Local Institution	Wellesley Hills	Massachusetts	United States
25	Local Institution	Lyons	New Jersey	United States
26	Local Institution	Albany	New York	United States
27	Local Institution	Lawrence	New York	United States
28	Local Institution	Montrose	New York	United States
29	Local Institution	Northport	New York	United States
30	Local Institution	White Plains	New York	United States
31	Local Institution	Raleigh	North Carolina	United States
32	Local Institution	Beachwood	Ohio	United States
33	Local Institution	Portland	Oregon	United States
34	Local Institution	Hershey	Pennsylvania	United States
35	Local Institution	Austin	Texas	United States
36	Local Institution	Dallas	Texas	United States
37	Local Institution	San Antonio	Texas	United States
38	Local Institution	Wichita Falls	Texas	United States
39	Local Institution	Bennington	Vermont	United States
40	Local Institution	Charlottesville	Virginia	United States
41	Local Institution	Seattle	Washington	United States

Sponsors and Collaborators

Otsuka Pharmaceutical Development & Commercialization, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

, ,

ClinicalTrials.gov Identifier:

NCT00036114

Other Study ID Numbers:

CN138-004

First Posted:

May 9, 2002

Last Update Posted:

Nov 11, 2013

Last Verified:

Apr 1, 2011

Keywords provided by , ,

Psychosis associated with dementia of the Alzheimer's type

Additional relevant MeSH terms:

Alzheimer Disease

Aripiprazole

Study Results

No Results Posted as of Nov 11, 2013